LIVMARLI

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
IA/0013	B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold	25/01/2024	n/a		
II/0009	Update of section 5.3 of the SmPC in order to update preclinical safety information based on final results from study MRX-NC-006, listed as a category 3 study in the RMP. This is a 104-week oral gavage carcinogenicity study of maralixibat in Sprague Dawley Rats performed to evaluate the toxicity and	18/01/2024		SmPC	Administration of maralixibat to rats resulted in no increases in tumour incidences in the final data of the presented study. Based on the negative outcome of the rat carcinogenicity study and the overall weight of evidence, no carcinogenic risk is anticipated for patients and chapter 5.3 SmPC has been updated accordingly. In addition, the

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	carcinogenic potential of maralixibat. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				detailed information in 5.3 of the SmPC that no effects on fertility were observed I female rats was deleted as not considered helpful for the prescriber.
IB/0010	B.II.f.1.b.2 - Stability of FP - Extension of the shelf life of the finished product - After first opening (supported by real time data)	07/12/2023		SmPC, Labelling and PL	
IB/0007	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	08/11/2023	n/a		
PSUSA/11032 /202303	Periodic Safety Update EU Single assessment - maralixibat	26/10/2023	n/a		PRAC Recommendation - maintenance
IAIN/0006	C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority	04/07/2023		Annex II	
II/0002	B.I.a.1.g - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new manufacturer of the AS that is not supported by an ASMF and requires significant update to the relevant AS section in the dossier	15/06/2023	n/a		
IA/0004/G	This was an application for a group of variations. A.5.b - Administrative change - Change in the name	01/06/2023	n/a		

	and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.f.1.e - Stability of FP - Change to an approved stability protocol				
II/0001/G	This was an application for a group of variations. B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	12/05/2023		SmPC	The SmPC section 6.3 has been updated as follows: Shelf-life (30 months)